Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HerXO: Trastuzumab + XELOX in HER2+ Gastric Cancer
NCT01503983Phase 2Completed
- Sponsor
- Fundación para el Progreso de la Oncología en Cantabria
- Start
- Aug 2011
- Primary completion
- Dec 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Fundación para el Progreso de la Oncología en Cantabria. Started Aug 2011; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01503983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01503983.